JNCCN study: Real world data shows impact of immunotherapy in populations underrepresented in clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients treated with first-line immunotherapy for advanced non-small cell lung cancer showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance, a study published in the Journal of the National Comprehensive Cancer Network showed.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
A three-year grant from Lilly to Roswell Park Comprehensive Cancer Center is bringing rich lung health resources to Indigenous workplaces located across North America. Collaborating with human resources specialists with Tribal Nations and communities covering many regions of the U.S. and Canada, Roswell Park’s Department of Indigenous Cancer Health team will provide lung cancer screening workflow resources, lung wellness education, and patient navigation services for thousands of eligible individuals.
Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login